Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411231 | 0.88 | KIT (0.52) | NAMPTKITGRM5KDM4ESPR | |
| SCHEMBL3413088 | 0.87 | GRM5 (0.58) | KITGRM5KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL3414673 | 0.87 | NAMPT (0.49) | NAMPTKITGRM5KDM4EHSP90AB1 | |
| SCHEMBL3414822 | 0.85 | GRM5 (0.49) | NAMPTKITGRM5KDM4EHSP90AA1 | |
| SCHEMBL3416965 | 0.84 | KIT (0.41) | NAMPTKITGRM5P2RX7KDM4E | |
| SCHEMBL3414890 | 0.84 | NAMPT (0.45) | NAMPTKITGRM5 | |
| SCHEMBL3414919 | 0.84 | GRM5 (0.50) | KITGRM5HSP90AA1HSP90AB1 | |
| SCHEMBL3414781 | 0.83 | GRM5 (0.49) | NAMPTKITGRM5P2RX7KDM4E | |
| SCHEMBL3413220 | 0.83 | KIT (0.44) | KITGRM5HSP90AB1HPGD | |
| SCHEMBL3410361 | 0.83 | GRM5 (0.51) | KITGRM5KDM4EHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | claimed |
| WO-2010124047-A1 | BISARYL ALKYNYLAMIDES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | GRM5, GRM1, GRM2 | NAMPT 4640/4885KIT 4672/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.